Literature DB >> 16633365

Ubiquitin ligases: cell-cycle control and cancer.

Keiichi I Nakayama1, Keiko Nakayama.   

Abstract

A driving force of the cell cycle is the activation of cyclin-dependent kinases (CDKs), the activities of which are controlled by the ubiquitin-mediated proteolysis of key regulators such as cyclins and CDK inhibitors. Two ubiquitin ligases, the SKP1-CUL1-F-box-protein (SCF) complex and the anaphase-promoting complex/cyclosome (APC/C), are responsible for the specific ubiquitylation of many of these regulators. Deregulation of the proteolytic system might result in uncontrolled proliferation, genomic instability and cancer. Cumulative clinical evidence shows alterations in the ubiquitylation of cell-cycle regulators in the aetiology of many human malignancies. A better understanding of the ubiquitylation machinery will provide new insights into the regulatory biology of cell-cycle transitions and the development of anti-cancer drugs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16633365     DOI: 10.1038/nrc1881

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  609 in total

Review 1.  Current treatment strategy and new agents in mantle cell lymphoma.

Authors:  Michinori Ogura
Journal:  Int J Hematol       Date:  2010-06-08       Impact factor: 2.490

2.  Radiosensitization of human pancreatic cancer cells by MLN4924, an investigational NEDD8-activating enzyme inhibitor.

Authors:  Dongping Wei; Hua Li; Jie Yu; Jonathan T Sebolt; Lili Zhao; Theodore S Lawrence; Peter G Smith; Meredith A Morgan; Yi Sun
Journal:  Cancer Res       Date:  2011-11-09       Impact factor: 12.701

Review 3.  Acetylation as a transcriptional control mechanism-HDACs and HATs in pancreatic ductal adenocarcinoma.

Authors:  Günter Schneider; Oliver H Krämer; Roland M Schmid; Dieter Saur
Journal:  J Gastrointest Cancer       Date:  2011-06

4.  Linking metabolism and cell cycle progression via the APC/CCdh1 and SCFβTrCP ubiquitin ligases.

Authors:  Shanshan Duan; Michele Pagano
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-15       Impact factor: 11.205

Review 5.  Regulation by S-nitrosylation of protein post-translational modification.

Authors:  Douglas T Hess; Jonathan S Stamler
Journal:  J Biol Chem       Date:  2011-12-06       Impact factor: 5.157

6.  Parkin Regulates Mitosis and Genomic Stability through Cdc20/Cdh1.

Authors:  Seung Baek Lee; Jung Jin Kim; Hyun-Ja Nam; Bowen Gao; Ping Yin; Bo Qin; Sang-Yeop Yi; Hyoungjun Ham; Debra Evans; Sun-Hyun Kim; Jun Zhang; Min Deng; Tongzheng Liu; Haoxing Zhang; Daniel D Billadeau; Liewei Wang; Emilie Giaime; Jie Shen; Yuan-Ping Pang; Jin Jen; Jan M van Deursen; Zhenkun Lou
Journal:  Mol Cell       Date:  2015-09-17       Impact factor: 17.970

Review 7.  Cell cycle, CDKs and cancer: a changing paradigm.

Authors:  Marcos Malumbres; Mariano Barbacid
Journal:  Nat Rev Cancer       Date:  2009-03       Impact factor: 60.716

8.  β-Trcp ubiquitin ligase and RSK2 kinase-mediated degradation of FOXN2 promotes tumorigenesis and radioresistance in lung cancer.

Authors:  Jia Ma; Yanwei Lu; Sheng Zhang; Yan Li; Jing Huang; Zhongyuan Yin; Jinghua Ren; Kai Huang; Li Liu; Kunyu Yang; Gang Wu; Shuangbing Xu
Journal:  Cell Death Differ       Date:  2018-02-02       Impact factor: 15.828

9.  HERC2 targets the iron regulator FBXL5 for degradation and modulates iron metabolism.

Authors:  Toshiro Moroishi; Takayoshi Yamauchi; Masaaki Nishiyama; Keiichi I Nakayama
Journal:  J Biol Chem       Date:  2014-04-28       Impact factor: 5.157

10.  Inactivation of SAG/RBX2 E3 ubiquitin ligase suppresses KrasG12D-driven lung tumorigenesis.

Authors:  Hua Li; Mingjia Tan; Lijun Jia; Dongping Wei; Yongchao Zhao; Guoan Chen; Jie Xu; Lili Zhao; Dafydd Thomas; David G Beer; Yi Sun
Journal:  J Clin Invest       Date:  2014-01-16       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.